At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 113 enrolled
Drug / intervention
MEDI0382 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects With a History of Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating MEDI0382 and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 113 participants across 11 sites.
Detailed Summary
A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in participants with Type 2 Diabetes Mellitus (T2DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartDec 2015
Primary CompletionFeb 2017
TodayJul 2026
First PostedSep 14, 2015
Enrollment StartDec 9, 2015
Primary CompletionFeb 24, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.8 years ago
Interventions
MEDI0382drug
MEDI0382 administered subcutaneously.
Placebodrug
Placebo administered subcutaneously.